Education
About Us
Working with TipRanks
Follow Us
Progyny (PGNY)
NASDAQ:PGNY
PGNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.39 - $33.84
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.57M
Market Cap
$1.87B
Enterprise Value$1.33B
Total Cash (Recent Filing)-$4.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)39.5
Beta0.66
Next Earnings
May 07, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding85,668,390
10 Day Avg. Volume1,301,069
30 Day Avg. Volume1,568,819
Financial Highlights & Ratios
PEG Ratio3.85
Price to Book (P/B)N/A
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)9.00
P/FCF Ratio9.30
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda19.23
Forecast
1Y Price Target
$27.14Price Target Upside24.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Progyny News
PremiumCompany Announcements
Progyny Director Fred Cohen to Step Down
PremiumCompany Announcements
Progyny, Inc. Reports Strong 2024 Earnings with Optimistic Outlook---
Bulls Say, Bears Say
Bulls Say
Government PolicyThe Trump Administration supports expanding access to IVF, which could positively impact PGNY.
Market SharePGNY is expected to gain significant market share, with health plans generally viewing it as high-quality and reasonably priced.
Bears Say
Consumption DeclineThe decline in consumption reported by PGNY may have been impacted by an increase in the unemployment rate.
EBITDA MarginsImplied adjusted EBITDA margin guidance is a little light versus estimates and consensus with the 16% midpoint a percentage point below FY24 margin of 17%.
---
Ownership Overview
8.30% Insiders
29.72% Mutual Funds
1.57% Other Institutional Investors
33.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $13.39 and its highest was $33.84 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $1.87B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is May 07, 2025 which is in 13 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Feb 27, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.096 by $0.024.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.19.
How many shares outstanding does Progyny have?
Progyny has 85,668,390 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.12 in its last earnings report, beating expectations of $0.096. Following the earnings report the stock price went down -1.53%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
---
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.14 (24.10% Upside)
$27.14 (24.10% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 762.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.08%
12-Months-Change
Fundamentals
Return on Equity
11.14%
Trailing 12-Months
Asset Growth
-19.80%
Trailing 12-Months
Company Description
Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
---
PGNY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive end to 2024 with strong revenue and client growth, high client retention, and successful new product launches. However, challenges include the loss of a major client, potential lower utilization rates, and increased investments impacting margins. Overall, the highlights outweigh the lowlights, indicating a positive outlook despite some hurdles.Read More>---
PGNY Stock 12 Month Forecast
Average Price Target
$27.14
▲(24.10% Upside)
Technical Analysis
Best Analysts Covering PGNY
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+11.57%
reiterated a buy rating 2 months ago
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +11.57% per trade.
---